Prescribing pattern of disease-modifying antirheumatic drugs in Scotland (2019–2023): a population-based retrospective cohort study
Expert Review of Clinical Pharmacology · 03.07.2025 · 18 (7) · 519-530
DOI: 10.1080/17512433.2025.2544038 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 04.08.2025. Verfasst von Amanj Kurdi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Scotland, Pharmacy, Glasgow, Scotland, UK. Hauptthemen laut MEDLINE: Antirheumatic Agents, Practice Patterns, Physicians', Rheumatic Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: funded.
Abstract (Originalsprache)
BACKGROUND: The increasing complexity of biologic and targeted therapies for inflammatory rheumatic diseases necessitates robust, real-world evidence to guide clinical decision-making. Scotland's newly established Homecare dataset, capturing ~ 90% of secondary care disease-modifying antirheumatic drugs (DMARDs) prescribing, offers a unique national resource to evaluate treatment patterns. RESEARCH DESIGN AND METHODS: We conducted a retrospective cohort study using Public Health Scotland's Homecare dataset (2019-2023), including 17,695 patients treated for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis (SpA), juvenile idiopathic arthritis (JIA), and related conditions. We analysed DMARD utilisation, treatment sequencing, and persistence using descriptive statistics and pathway mapping. RESULTS: A total of 260,054 prescriptions were analysed, with biologic DMARDs comprising 90% of homecare supplies. Adalimumab and etanercept were the predominant agents. TNF inhibitors dominated first-line use, with high persistence rates (78.6%-97.1%), particularly in JIA and SpA. Among switchers, median time on initial therapy was 10.7 months (IQR: 4.2-23.3), decreasing with each subsequent treatment, highlighting the challenges in managing multi-refractory patients. CONCLUSION: This is the first national study to characterise real-world DMARD prescribing in Scotland using comprehensive Homecare data. Findings provide critical benchmarks for therapeutic optimisation, inform guideline development, and support sustainable planning for high-cost medicines delivery in rheumatology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Public Health Scotland, Pharmacy, Glasgow, Scotland, UK.
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
- Department of Clinical Pharmacy, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
- College of Pharmacy, Al-Kitab University, Kirkuk, Iraq.
- Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
Förderung
- funded
Zitieren
APA
Kurdi, A., Proud, E., Stobo, L., Millar, M., Clayton, W., McTaggart, S., Mueller, T., & Bennie, M. (2025). Prescribing pattern of disease-modifying antirheumatic drugs in Scotland (2019–2023): a population-based retrospective cohort study. Expert Review of Clinical Pharmacology, 18(7), 519-530. https://doi.org/10.1080/17512433.2025.2544038
Vancouver
Kurdi A, Proud E, Stobo L, Millar M, Clayton W, McTaggart S, et al. Prescribing pattern of disease-modifying antirheumatic drugs in Scotland (2019–2023): a population-based retrospective cohort study. Expert Review of Clinical Pharmacology. 2025;18(7):519-530. doi:10.1080/17512433.2025.2544038
BibTeX
@article{Kurdi2025,
author = {Kurdi, Amanj and Proud, Euan and Stobo, Laura and Millar, Morven and Clayton, Will and McTaggart, Stuart and Mueller, Tanja and Bennie, Marion},
title = {Prescribing pattern of disease-modifying antirheumatic drugs in Scotland (2019–2023): a population-based retrospective cohort study},
journal = {Expert Review of Clinical Pharmacology},
year = {2025},
volume = {18},
number = {7},
pages = {519--530},
doi = {10.1080/17512433.2025.2544038}
}
EUVIMED